NASDAQ:MRUS
Merus NV Stock News
$56.78
-0.130 (-0.228%)
At Close: Jun 25, 2024
UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, fu
Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting
12:30pm, Sunday, 02'nd Jun 2024
UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 02, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, fu
Merus Announces Pricing of Upsized Public Offering of Common Shares
09:30pm, Wednesday, 29'th May 2024
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), a clinical-stage oncology company de
Merus to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference
08:00am, Wednesday, 29'th May 2024
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies
Merus N.V. Announces Proposed Public Offering of Common Shares
04:01pm, Tuesday, 28'th May 2024
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), a clinical-stage oncology company de
67% response rate observed among 24 evaluable patients Conference Call on Tuesday, May 28 th at 8 a.m. ET UTRECHT, The Netherlands and CAMBRIDGE, Mass.
Merus (MRUS) Surges 36% on Head & Neck Cancer Antibody Data
12:41pm, Monday, 27'th May 2024
Data from an earlier cut-off date shows that treatment with Merus' (MRUS) combination therapy achieved a 60% response rate in patients with head and neck cancer.
Merus Stock: Priced High After An ASCO Surprise Surge (Maintain Buy)
01:00pm, Friday, 24'th May 2024
Merus N.V. is experiencing significant growth and entering a higher price territory, making the risk-reward less clear. The company's bispecific antibody, petosemtamab, showed promising results in a p
Merus Announces Publication of Abstracts for Presentation at the 2024 ASCO® Annual Meeting
05:00pm, Thursday, 23'rd May 2024
MCLA-145 monotherapy and in combination with pembrolizumab rapid oral session presentation: June 2, 2024, 11:30 a.m.-1:00 p.m. CT
- 60% response rate observed among 10 evaluable patients - F avorable safety profile in 26 patients enrolled as of the abstract cutoff date , with no significant overlapping toxicities observe
Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDA
08:00am, Monday, 13'th May 2024
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies
Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update
04:15pm, Wednesday, 08'th May 2024
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, ful
If approved, Zeno will be the first targeted therapy for NRG1+ cancer If approved, Zeno will be the first targeted therapy for NRG1+ cancer
Merus (MRUS) Moves 7.1% Higher: Will This Strength Last?
09:01am, Friday, 26'th Apr 2024
Merus (MRUS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Will Merus N.V. (MRUS) Report Negative Q1 Earnings?
11:07am, Thursday, 25'th Apr 2024
Merus (MRUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
